A5009305574- Cancer Immunotherapy and Biomarkers
- Cancer-related molecular mechanisms research
- Lung Cancer Treatments and Mutations
- Ferroptosis and cancer prognosis
- Epigenetics and DNA Methylation
- Lung Cancer Research Studies
- MicroRNA in disease regulation
- Radiomics and Machine Learning in Medical Imaging
- Medical Imaging Techniques and Applications
- Thyroid Cancer Diagnosis and Treatment
- Chromatin Remodeling and Cancer
- Neuroblastoma Research and Treatments
- Neuroendocrine Tumor Research Advances
- Cancer Research and Treatments
- Tumors and Oncological Cases
- HER2/EGFR in Cancer Research
- CAR-T cell therapy research
- Gastric Cancer Management and Outcomes
- Multiple Myeloma Research and Treatments
- Immunotherapy and Immune Responses
- Head and Neck Cancer Studies
- Melanoma and MAPK Pathways
- Extracellular vesicles in disease
- Cancer Genomics and Diagnostics
- Soft tissue tumor case studies
Hokkaido University Hospital
2025
Daido University
2025
Hokkaido University
2014-2024
Sapporo Medical University
2018-2024
Precision medicine plays an important role in the treatment of patients with advanced melanoma. Despite its high incidence White patients, melanoma is rare Asian countries, hampering prospective clinical trials targeting population. This retrospective study aimed to elucidate real-world molecular diagnoses and outcomes Japanese using comprehensive genome profiling (CGP). Patients who completed standard anticancer medical treatments (including those expected complete treatments) underwent...
Abstract Background: Pathological complete response (pCR) following neoadjuvant chemotherapy (NAC) is positively correlated with long-term event-free survival and overall in patients triple-negative breast cancer (TNBC). However, the molecular subtypes of TNBC associated pCR remain to be elucidated. Methods: We conducted a transcriptomic clinical outcome analysis 28 who underwent surgery NAC at Hokkaido University Hospital Cancer Center Japan between 2017 2022. The research protocol was...
Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) elicit potent cell cycle arrest in EGFR-mutant non-small-cell lung cancer (NSCLC) cells. However, little is known about the mechanisms through which these drugs alter tumor phenotype that contributes to immune escape of Using NSCLC lines and tissue samples from patients, we investigated changes checkpoints expressed cells following EGFR inhibition. Subsequently, also analyzed role soluble factors dying activation...
Crystalline silica-induced inflammation possibly facilitates carcinogenesis. Here, we investigated its effect on lung epithelium damage. We prepared conditioned media of immortalized human bronchial epithelial cell lines (hereinafter lines) NL20, BEAS-2B, and 16HBE14o- pre-exposed to crystalline silica (autocrine medium), a phorbol myristate acetate-differentiated THP-1 macrophage line, VA13 fibroblast line (paracrine medium). As cigarette smoking imposes combined carcinogenesis, medium was...
Lenvatinib, an oral molecular targeted drug, is used to treat patients with unresectable or advanced thyroid carcinoma that refractory radioiodine treatment. Effective methods for evaluating drugs are a critical unmet need owing their expensive costs and unique adverse events. The aim of this study determine whether 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT at 1 week after commencing lenvatinib can predict treatment outcomes. This planned as non-randomised single-arm...
Immune checkpoint inhibitors (ICIs) have expanded therapeutic options for advanced malignancies, offering new hope conditions once deemed untreatable. However, the advent of ICIs has introduced a spectrum immune-related adverse events (irAEs), including leukocytoclastic vasculitis (LCV), rare but significant complication. This case report describes development LCV after treatment with nivolumab and ipilimumab in 70-year-old man malignant melanoma, highlighting diagnostic management...
Lenvatinib is widely used to treat unresectable and advanced thyroid carcinomas. We aimed determine whether 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) performed 1 week after lenvatinib treatment initiation could predict outcomes. This was a prospective, nonrandomised, multicentre study. Patients with pathologically confirmed differentiated carcinoma (DTC) lesions refractory radioiodine were eligible for inclusion. treated 24 mg as the initial dose...
Solitary fibrous tumor (SFT) is a rare subtype of soft tissue sarcoma (STS). We herein describe case late onset non-islet cell hypoglycemia (NICTH) that was managed via multidisciplinary treatment in patient with SFT. A 67-year-old man previously diagnosed SFT 4 years prior to this presentation and treated several rounds surgery, presented massive tumors. Eighteen months following his prescribed chemotherapy, the developed hypoglycemia. He NICTH, after confirming presence high molecular...
Abstract EGFR-tyrosine kinase inhibitors (TKIs) benefit patients with EGFR-mutant non-small cell lung cancer (NSCLC). Still, the majority of eventually develop resistance to therapy. This study thus explored therapeutic targets overcome this immunologically. Our screening in public database and vitro confirmatory experiments revealed that expression innate immune checkpoint CD24 was induced NSCLC lines such as PC9 H1975 when treated EGFR-TKIs. Immunohistochemistry tissue samples from who...
Abstract Epigenetic alteration contributes to tumor initiation, progression and invasion. machinery has become a major focus for the new development of molecular targeted cancer therapeutics. H3K4 trimethylation (H3K4me3) is an epigenetic mark which exist surrounding transcription start site have been presumed be associated with stem like cells. JARID1 family demethylase H3K4me2/me3. Especially, JARID1a JARID1b suggested oncogenic properties in several cancers, including lung cancer. Here we...
Abstract Epigenetic alteration contributes to tumor initiation, progression and invasion. machinery has become a major focus for the new development of molecular targeted cancer therapeutics. H3K4 trimethylation (H3K4me3) is epigenetic marks which exist surrounding transcription start site active genes. JARID1 family demethylase H3K4me2/me3. JARID1a JARID1b have been suggested, especially oncogenic properties associations with anti-cancer drug resistance. We previously showed that inhibitor,...
Epigenetic alteration contributes to tumor initiation, progression and invasion. machinery has become a major focus for the new development of molecular targeted cancer therapeutics. H3K4 trimethylation (H3K4me3) is epigenetic marks which exist surrounding transcription start site active genes. JARID1 family demethylase H3K4me2/me3. JARID1a JARID1b have been suggested, especially oncogenic properties associations with anti-cancer drug resistance. We previously showed that inhibitor,...